Recent 8-K filings for ALMR

• September 1, 2026, 4:01 PM ET leadership materiality 0.20 neutral item 5.02 ◈ executive_change

  Alamar Biosciences appoints Robert Ragusa to board as Class I director

  Robert Ragusa appointed to Alamar Biosciences board effective Sept 1, 2026.

• August 10, 2026, 4:10 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Alamar Q2 revenue $29.4M (+82% YoY); guides FY26 to $116-120M

  Q2 revenue $29.4M, up 82% from $16.2M YoY; consumables +147% to $15.5M, instruments +35% to $7.8M.

• July 15, 2026, 4:04 PM ET leadership materiality 0.40 negative item 8.01

  Alamar Biosciences announces death of board member Ian Ratcliffe; board size reduced to five

  Independent director Ian Ratcliffe, who served since February 2024, passed away on July 5, 2026.

• May 8, 2026, 7:59 PM ET earnings materiality 0.78 positive item 2.02item 9.01 ◈ Earnings Releases

  Alamar Q1 revenue doubled to $26.0M; net loss $21.3M on convertible note remeasurement

  Total revenue $26.0M, +99% YoY; consumable revenue surged 178% to $14.0M.

• April 20, 2026, 7:59 PM ET other material materiality 0.85 positive item 5.03item 8.01item 9.01 ◈ Governance Changes ×2

  Alamar Biosciences closes IPO of 12.9M shares at $17.00, raising ~$219.9M

  Completed IPO of 12,937,500 shares of common stock at $17.00 per share, including full exercise of underwriters' option for 1,687,500 shares.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.78 · Most common event leadership

3 positive 1 negative 1 neutral

source · ALMR on sec.gov